Literature DB >> 21119606

Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.

Sevdalina Lambova, Ulf Müller-Ladner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21119606     DOI： 10.1038/nrrheum.2010.207

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.

Authors:  M Humbert; J Cabane
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

Review 2.  Endothelin--role in vascular disease.

Authors:  D Abraham; M Dashwood
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

3.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

4.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Authors:  M Rademaker; E D Cooke; N E Almond; J A Beacham; R E Smith; T G Mant; J D Kirby
Journal:  BMJ       Date:  1989-03-04

5.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.

Authors:  R Scorza; M Caronni; B Mascagni; V Berruti; S Bazzi; E Micallef; G Arpaia; M Sardina; L Origgi; M Vanoli
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

6.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Authors:  U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

7.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study.

Authors:  Eric Hachulla; Pierre Clerson; David Launay; Marc Lambert; Sandrine Morell-Dubois; Viviane Queyrel; Pierre-Yves Hatron
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

8.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

9.  Registry evaluation of digital ulcers in systemic sclerosis.

Authors:  Felice Galluccio; Marco Matucci-Cerinic
Journal:  Int J Rheumatol       Date:  2010-08-25

10.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Authors:  Marco Matucci-Cerinic; Christopher P Denton; Daniel E Furst; Maureen D Mayes; Vivien M Hsu; Patrick Carpentier; Fredrick M Wigley; Carol M Black; Barri J Fessler; Peter A Merkel; Janet E Pope; Nadera J Sweiss; Mittie K Doyle; Bernhard Hellmich; Thomas A Medsger; Adele Morganti; Fabrice Kramer; Joseph H Korn; James R Seibold
Journal:  Ann Rheum Dis       Date:  2010-08-30       Impact factor: 19.103
  10 in total
  1 in total

1.  Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.

Authors:  Sonja Hetzer; Bettina Alexandra Buhren; Holger Schrumpf; Edwin Bölke; Stephan Meller; Kai Kammers; Peter Arne Gerber; Bernhard Homey
Journal:  Eur J Med Res       Date:  2014-01-10       Impact factor: 2.175
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.